These benefits, along with a former report demonstrating that a small-molecule ACKR3 agonist CCX771 reveals anxiolytic-like conduct in mice,2 support the thought of focusing on ACKR3 as a unique strategy to modulate the opioid process, which could open new therapeutic avenues for opioid-associated Ailments.Conolidine CONOCB2™ effectively operates